Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor

Rhea-AI Summary

Resmed (NYSE: RMD) announced that director Carol Burt has been appointed to become Lead Director effective November 15, 2026, succeeding Ron Taylor. Taylor, who has served on Resmed’s board since 2005 and as Lead Director since 2013, will not stand for reelection at the 2026 Annual Meeting of Stockholders on November 18, 2026 and will retire after more than 21 years of service. Burt has been a director since 2013, chairs the Nominating and Governance Committee, and serves on the Audit and Compliance, Privacy and Quality Committees, which Resmed highlights as strong preparation for her Lead Director role.

Positive

• Lead Director succession date set for November 15, 2026, providing clarity on governance transition
• Experienced internal director Carol Burt promoted, with board service since 2013 and multiple committee roles
• Governance continuity supported by appointing current Nominating and Governance Committee chair as Lead Director

Negative

• Retirement of Ron Taylor after 21+ years removes long-tenured board experience and historical perspective

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Nominating and Governance Chair Carol Burt to become Lead Director.
• Ron Taylor to retire after more than 21 years of service on Resmed’s Board of Directors.

SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Carol Burt will become Lead Director on November 15, 2026. She will succeed Ron Taylor, Resmed’s current Lead Director, who is not standing for reelection at the company’s 2026 Annual Meeting of Stockholders on November 18, 2026, and will retire after more than 21 years of service to the company.

The Board has appointed Carol Burt to serve as Lead Director, effective November 15, 2026. Burt has served on Resmed’s Board since 2013 and currently chairs the Nominating and Governance Committee. She is also a member of the Audit Committee and the Compliance, Privacy and Quality Committee. Burt's extensive board leadership and governance experience position her well to serve as Lead Director as the company continues to execute its long-term strategy.

“Carol is an outstanding leader with deep governance experience, broad healthcare industry knowledge and a strong commitment to Resmed's mission,” said Mick Farrell, Resmed’s Chairman and CEO. “I look forward to continuing to work closely with Carol and the entire Board as we advance our strategy and create long-term value for our shareholders.”

Ron Taylor joined Resmed’s Board of Directors in 2005 and has served in numerous leadership roles, including as Lead Director since 2013. During his tenure, Ron helped guide the company's governance, strategy and long-term growth while providing thoughtful leadership and independent oversight during a period of significant growth and transformation.

“Ron has made extraordinary contributions to Resmed over the past two decades,” said Farrell. “His integrity, sound judgment and unwavering commitment to our patients, employees and shareholders have helped shape Resmed. On behalf of the Board and all Resmedians, I thank Ron for his outstanding service and wish him and his family all the very best.”

About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more at Resmed.com and follow @Resmed.

For Media
Brad Lotterman
Brad.Lotterman@resmed.com
News@resmed.com

For Investors 
Salli Schwartz
Salli.Schwartz@resmed.com
investorrelations@resmed.com  

FAQ

What leadership change did Resmed (RMD) announce on August 17, 2026?

Resmed announced that Carol Burt will become Lead Director on November 15, 2026, succeeding Ron Taylor. According to Resmed, Taylor will not stand for reelection at the 2026 Annual Meeting and will retire after more than 21 years on the board.

When will Carol Burt assume the Lead Director role at Resmed (RMD)?

Carol Burt is scheduled to become Lead Director on November 15, 2026. According to Resmed, the board has appointed her effective that date, ahead of the 2026 Annual Meeting of Stockholders set for November 18, 2026, ensuring an orderly governance transition.

Who is Carol Burt and what is her background on Resmed’s (RMD) board?

Carol Burt is a Resmed director since 2013 and chair of the Nominating and Governance Committee. According to Resmed, she also serves on the Audit and Compliance, Privacy and Quality Committees, bringing extensive governance and healthcare industry experience to the Lead Director role.

When is Ron Taylor retiring from Resmed’s (RMD) board and what has been his role?

Ron Taylor will retire after Resmed’s 2026 Annual Meeting on November 18, 2026. According to Resmed, he joined the board in 2005, has served as Lead Director since 2013, and contributed to governance, strategy and long-term growth over more than 21 years.

Why is the Lead Director transition at Resmed (RMD) important for shareholders?

The Lead Director transition clarifies Resmed’s board leadership and governance oversight. According to Resmed, appointing experienced director Carol Burt, who leads Nominating and Governance and serves on key committees, supports continuity as the company executes its long-term strategy and focuses on shareholder value.

What committees does new Lead Director Carol Burt serve on at Resmed (RMD)?

Carol Burt chairs the Nominating and Governance Committee and serves on the Audit and Compliance, Privacy and Quality Committees. According to Resmed, this combination of responsibilities reflects broad governance involvement that the company views as strong preparation for her upcoming Lead Director role.